Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by MarketMoneyon Jan 05, 2021 2:43pm
174 Views
Post# 32225441

RE:RE:EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE

RE:RE:EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE
LithLover wrote: Makes no sense that we would be sitting at a market cap of $44 million.  


Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.

InvestManOne wrote: EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE EARLIER
DETECTION, CREATING A LEADER IN BLOOD-BASED, MULTI-CANCER SCREENING 
JAN 5, 2021

https://money.tmx.com/en/quote/EXAS:US/news/6819844710375101/Exact_Sciences_Completes_Acquisition_of_Thrive_Earlier_Detection_Creating_a_Leader_in_BloodBased_MultiCancer_Screening
 




 

look at Tesla market cap.....makes no sense? Remember the stock evaluation is based on actual demand and supply of the shares.....bid and ask........when a stock is in demand the valuation goes up no matter if they make money or not, no matter if they have debt or not, no matter if they have revenu or not...it's always at the end the demand and supply of the shares that determine the shareprice!!!

<< Previous
Bullboard Posts
Next >>